as 05-20-2024 4:00pm EST
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 48.8M | IPO Year: | N/A |
Target Price: | $4.50 | AVG Volume (30 days): | 725.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.32 | EPS Growth: | N/A |
52 Week Low/High: | $0.27 - $1.02 | Next Earning Date: | 05-14-2024 |
Revenue: | $2,817,187 | Revenue Growth: | -71.83% |
Revenue Growth (this year): | 152.93% | Revenue Growth (next year): | 379.22% |
DARE Breaking Stock News: Dive into DARE Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
5 days ago
GuruFocus.com
6 days ago
GlobeNewswire
6 days ago
GlobeNewswire
13 days ago
GlobeNewswire
18 days ago
GlobeNewswire
20 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago